Profile: Novartis AG (NVS.N)
Novartis AG, incorporated on March 1, 1996, is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's range of products includes innovative pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines is engaged in various prescription medicines. Sandoz is engaged in Generic pharmaceuticals and biosimilars. Alcon is engaged in Surgical and vision care products.
Innovative Medicines researches, develops, manufactures, distributes and sells prescription medicines to develop health outcomes for patients and healthcare providers. The Innovative Medicines is organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. The Novartis Oncology business unit is responsible for the commercialization of products in the therapeutic area of oncology. Novartis Pharmaceuticals consists of the global business franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic and established medicines.
The Novartis Oncology Business Unit's products include Afinitor/Votubia and Afinitor Disperz/Votubia dispersible tablets, Arzerra, Exjade and Jadenu, Farydak, Femara, Gleevec/Glivec, Jakavi, Proleukin, Promacta/Revolade, Sandostatin LAR and Sandostatin SC, Signifor and Signifor LAR, Tafinlar + Mekinist, Tasigna, Tykerb, Votrient, Zometa and Zykadia. The Novartis Pharmaceuticals Business Unit's Ophthalmology products include Azarga/Azorga; Duotrav; Durezol; Lucentis; Pataday and Pazeo; Patanol; Simbrinza; Systane and Systane Ultra; Systane Balance; Systane Hydration, and Travatan, Travatan Z, Travatan BAK-Free, Izba.
The Novartis Pharmaceuticals Business Unit's Neuroscience products include Extavia and Gilenya. The Novartis Pharmaceuticals Business Unit's Immunology and Dermatology products include Cosentyx, Ilaris, Myfortic, Neoral/Sandimmune, Simulect, Xolair and Zortress/ Certican. The Novartis Pharmaceuticals Business Unit's Respiratory products include Onbrez Breezhaler, Seebri Breezhaler, Ultibro Breezhaler and Xolair. The Novartis Pharmaceuticals Business Unit's Cardio-Metabolic products include Entresto, Eucreas and Galvus. The Novartis Pharmaceuticals Business Unit's Established Medicines include Cibacen, Comtan, Diovan, Diovan HCT/Co-Diovan, Exelon, Exforge, Exforge HCT, Focalin and Focalin XR, Lamisil, Lescol and Lescol XL, Ritalin, Ritalin LA, Stalevo, Tegretol, TOBI and TOBI Podhaler, Trileptal, Tyzeka/Sebivo and Voltaren/Cataflam.
The Company's Gleevec/Glivec (imatinib mesylate/imatinib) is a kinase inhibitor approved as a targeted therapy for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and to treat patients with metastatic and/or unresectable KIT (CD117) positive (KIT+) gastrointestinal stromal tumors (GIST), and as an adjuvant treatment for certain adult patients following resection of KIT+ GIST. Tasigna (nilotinib) is a signal transduction inhibitor of the BCR-ABL tyrosine kinase. Sandostatin SC and Sandostatin LAR (octreotide acetate/octreotide acetate for injectable suspension) are somatostatin analogues indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Afinitor/Votubia (everolimus) is an oral inhibitor of the mechanistic target of rapamycin (mTOR) pathway. Exjade and Jadenu (deferasirox) is an oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older, as well as chronic iron overload in patients with non-transfusion dependent thalassemia in patients 10 years of age and older.
Votrient (pazopanib) is a small molecule tyrosine kinase inhibitor that targets a number of intracellular proteins to limit tumor growth and cell survival. Tafinlar + Mekinist (dabrafenib + trametinib) is the combination for the treatment of patients with BRAF V600 mutation positive unresectable or metastatic melanoma, as detected by a validated test. Promacta/Revolade (eltrombopag) is a once-daily oral thrombopoietin receptor agonist that works by stimulating bone marrow cells to produce platelets. Jakavi (ruxolitinib) is an oral inhibitor of the JAK1 and JAK2 tyrosine kinases. Lucentis (ranibizumab) is a recombinant humanized high affinity antibody fragment that binds to vascular endothelial growth factor A (VEGF-A), a key mediator of intraocular neovascularization.
Travatan (travoprost), Travatan Z (travoprost) and Duotrav (travoprost/timolol) are indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or patients having ocular hypertension. Systane (polyethylene glycol 400 and propylene glycol) and other Systane branded products are indicated for the temporary relief of burning and irritation due to dryness of the eye. Patanol (olopatadine), Pataday (olopatadine) and Pazeo (olopatadine) are olopatadine hydrochloride ophthalmic solutions of different concentrations that are approved to treat the signs and symptoms of allergic conjunctivitis (Patanol), as well as ocular itching associated with allergic conjunctivitis (Pataday and Pazeo). Gilenya (fingolimod) is the oral therapy approved to treat relapsing forms of multiple sclerosis (RMS) and the first in a new class of compounds called sphingosine 1-phosphate receptor modulators.
Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Sandoz is organized globally in three franchises: Retail Generics, Anti-Infectives, and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals to third parties. Retail Generics includes the areas of dermatology, respiratory, oncology, ophthalmics, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies, as well as finished dosage form anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein or other biotechnology based products, including biosimilars, and provides biotechnology manufacturing services to other companies.
The marketed products in the Sandoz portfolio include multiple sclerosis treatment Glatopa (glatiramer acetate injection) 20 milligrams (mg)/milliliters (mL), respiratory inhaler therapy AirFluSal Forspiro (fluticasone salmeterol), and pain medication fentanyl, which is delivered using a transdermal patch. Sandoz is a provider of biosimilars, including Omnitrope, a human growth hormone; Binocrit, an erythropoiesis-stimulating agent used to treat anemia; and filgrastim for neutropenia under the brand names Zarzio and Zarxio. Its biosimilar Erelzi (etanercept-szzs) is to treat multiple inflammatory diseases. Its biosimilar Binocrit (epoetin alfa) is based on data from a study in pre-dialysis and dialysis patients with anemia associated with chronic kidney disease.
Sandoz offers a range of products in various countries, including ACC solution for injection; Amphetamine salts extended release (Shire's Adderall XR); Buprenorphine four- and seven-day transdermal therapeutic system, matrix patch (Mundipharma's BuTrans, Norspan); Calcipotriol bethametasone ointment (Leo Pharma's Dovobet); Esomeprazole MUT (Astra Zeneca's Nexium); Fluticasone salmeterol powder dose inhaler (GSK's Seretide); Linezolid solution for infusion/injection (Pfizer's Zyvox)/Linezolid film coated tablet (Pfizer's Zyvoxid); Mometasone furoate (Nasonex nasal spray), and Oxiconazole nitrate (Oxistat). As of December 31, 2016, Sandoz marketed approximately 1,000 molecules in countries around the world.
Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. Alcon is organized into two global business franchises: Surgical and Vision Care. The Surgical franchise includes technologies and devices for cataract, retinal, glaucoma and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors, like presbyopia and astigmatism. Alcon also provides viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery. The Vision Care franchise consists of daily disposable, monthly replacement, and color-enhancing contact lenses, as well as a complete line of contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops and daily protein removers.
Alcon's Surgical portfolio includes the Cataract Refractive Suite by Alcon, a suite of equipment to enable, plan and perform cataract surgery with automation and care. It consists of the Centurion vision system phacoemulsification technology platform; the LenSx laser, a femtosecond laser for increased precision and reproducibility for the corneal incision, capsulorhexis and lens fragmentation steps of the procedure; the Verion image guided system, an ocular surgical planning, imaging and guidance technology; the outer rhabdomeres absent (ORA) System, an intra-operative guidance system for Intra ocular lens (IOLs) implantation during cataract surgery; and the LuxOR LX3 surgical microscope for visualization during surgery.
Alcon's Surgical portfolio also includes the Wavelight refractive suite portfolio for Laser-Assisted in situ Keratomileusis (LASIK) treatments and other refractive procedures, including topography-guided procedures marketed under the Contoura name, the constellation vision system for retinal operations, and the Infiniti vision system to perform cataract surgeries, which is the phacoemulsification platform introduced prior to the Centurion vision system. Alcon also offers the AcrySof family of IOLs to treat cataracts, including monofocal, toric (astigmatism-correcting), and multifocal (presbyopia-correcting) options. The AcrySof IQ PanOptix presbyopia-correcting IOL is a hydrophobic acrylic trifocal IOL designed to provide functional vision from near to intermediate, in addition to providing distance vision comparable to that of a monofocal lens. In addition, Alcon provides viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.
Alcon's Vision Care franchise develops and markets contact lenses and lens care products. Alcon's portfolio of silicone hydrogel, daily disposable and color contact lenses includes its Air Optix, Dailies and Freshlook brands. Its Dailies product line includes the Dailies Total1 lens, a water gradient contact lens, which is also offered in a multifocal option for patients with presbyopia. Its Air Optix monthly replacement product line features silicone hydrogel contact lenses in monofocal, astigmatism-correcting, and multifocal options, as well as Air Optix Colors and Air Optix plus HydraGlyde contact lenses. Its contact lens care solutions business includes the Opti-Free line of multi-purpose disinfecting solutions, as well as the Clear Care and AOSept Plus line of hydrogen peroxide lens care solutions.
Alcon offers a range of products, including CyPass Micro-Stent, a micro invasive glaucoma surgery (MIGS) device, was launched in the United States to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery; NGENUITY 3D Visualization System was launched in the United States and European Union to provide surgeons visualization by combining a three dimensional (3D) camera, image optimization, polarizing surgeon glasses to create a platform for digitally assisted Vitreoretinal surgery (DAVS), and AcrySof IQ ReSTOR 3.0D Toric IOL, to address presbyopia and preexisting astigmatism at the time of cataract surgery in adult patients. Alcon has launched Air Optix plus HydraGlyde, an upgrade to silicon hydrogel contact lenses featuring HydraGlyde Moisture Matrix technology for lens surface wettability, and has also launched Dailies Total1 Multifocal contact lenses in the United States and European Union to provide refractive correction with distance, intermediate and near vision for people with presbyopia.
Company Web Links
- Momenta seeks $938 million from Amphastar at drug patent trial's end
- Novartis sees Alcon recovery opening door to spin-off IPO
- UPDATE 2-Novartis sees Alcon recovery opening door to spin-off IPO
- BRIEF-Novartis 'cooperating fully' with DOJ, SEC probe of Alcon's Russia, Asia business
- BRIEF-Novartis CEO says growth at Alcon boosts options for eye surgery unit